The utility of point-of-care biomarkers as a prognostic tool for patients with acute coronary syndromes
1Department of Emergency Medicine, Korea University Guro Hospital, Gurogu, Seoul, Korea
2 Department of Emergency Medicine, Korea University Anam Hospital, Sungbukgu, Seoul, Korea
DOI: 10.22514/SV131.052017.27 Vol.13,Issue 1,March 2017 pp.89-94
Published: 20 March 2017
Introduction. Patients with symptoms suggestive of acute coronary syndrome (ACS) have various medical backgrounds and different stages of underlying coro-nary disease. Hence, patients entering the emergency room (ER) with ACS sug-gestive symptoms, present a challenge to emergency physicians. We hypothesized that a point-of-care test (POCT) for mul-tiple cardiac biomarkers can be used as a prognostic tool for predicting severity and hospital mortality in acute myocardial in-farction (AMI) patients.
Methods . We conducted a retrospective analysis of all patients who presented to the ER of a university urban hospital with chest pain, chest discomfort and short-ness of breath of potential cardiovascular origin during a 3-year period. Biomarkers from the POCT and coronary angiography (CAG) results were used for diagnosis. Se-verity was evaluated based on involvement and status of major coronary arteries, ejec-tion fraction and in-hospital mortality. Results. Out of 1336 patients, 329 patients were diagnosed with AMI. Risk of major coronary artery occlusion was increased with an increased number of positive POCT findings. The percentage of patients with severe left ventricular dysfunction was higher in the group with 2 or 3 posi-tive POCTs than 0 or 1. As the number of positive POCTs increased from 1 to 3, our results showed an increment in the per-centage of in-hospital mortality Conclusions. This study identified the pos-sibility of a POCT as a prognostic tool. The POCT is easy to use by the bedside and can be checked relatively quickly? in a short period of time. If the POCT result is used to predict the prognosis in ACS patients, emergency physicians may approach pa-tients with more caution.
chest pain, shortness of breath, acute myocardial infarction, in-hospital mortality
YOUNG-DUCK CHO,SUNG-WOO LEE,YOUNG-HOON YOON,JUNG-YOUN KIM,JONG-HAK PARK,SUNG-HYUK CHOI. The utility of point-of-care biomarkers as a prognostic tool for patients with acute coronary syndromes. Signa Vitae. 2017. 13(1);89-94.
1. Punukollu H, Khan IA, Punukollu G, Gowda RM, Mendoza C, Sacchi TJ. Acute pulmonary embolism in elderly: clinical character-istics and outcome. Int J Cardiol 2005;99:213-6.
2. Godfrey C, Harrison MB, Medves J, Tranmer JE. The symptom of pain with heart failure: a systemic review. J Card Fail 2006;12:307-13.
3. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004;126:461-9.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992;326:310-8.
5. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006;48:1-11.
6. Sciria BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol 2010;55:1403-15.
7. Fesmire FM, Decker WW. Diercks DB, Ghaemmaghami CA, Nazarian D, Brady WJ, Hahn S, Jagoda AS; American College of Emer-gency Physicians Clinical Policies Subcommittee (Writing Committee) on Non-ST-Segment Elevation Acute Coronary Syndromes. Clinical policy: critical issues in the evaluation and management of adult patient with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med 2006;48:207-301.
8. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, Apple FS, Francis G, Tang W; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007;53:552-74.
9. Harrison A, Amundson S. Evaluation and management of the acutely dyspneic patient: the role of biomarkers. Am J Emerg Med 2005;23:371-8.
10. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67.
11. Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thomson TD, Lee KL, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation 1998; 98:1853-9.
12. Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina accord-ing to troponin T status. Circulation 1999;100:1509-14.
13. Okamatsu K, Takano M, Sakai S, Ishibashi F, Uemura R, Takano T, et al. Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation 2004;109:465-70.
14. Januzzi JL, van Kimmenade T, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international Col-laborative of NT-proBNP Study. Eur Heart J 2006;27:330-7.
15. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004;6:257-60.
16. Wiviott SD, de Lemos JA, Morrow DA. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta 2004;346:119-28.
17. James SK, Lindhal B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery dis-ease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
18. Kearon C, Ginsberg JS, Douketis J, Turpie AG, Bates SM, Lee AY, et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med 2006;144:812-21.
19. Righini M, Perrier A, De Moerloose P and Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008;6:1059-71.
20. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous throm-boembolism: an overview. J Thromb Haemost. 1994;71:1-6.
21. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005;26:1765-73.
22. Becattini C, Lignani A, Masotti L, Forte MB and Agnelli G. D-dimer for risk stratification in patients with acute pulmonary embo-lism. J Thromb Thrombolysis 2012;33:48-57.
23. Goldhaber SZ, Simons GR, Elliott CG, Haire WD, Toltzis R, Blacklow SC, et al. Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA 1993;270:2819-22.
24. Abcarian PW, Sweet JD, Watabe JT, Yoon HC. Role of a quantitative D-dimer assay in determining the need for CT angiography of acute pulmonary embolism. AJR Am J Roentgenol. 2004;182:1377-81.
25. Kabrhel C, Mark Courtney D, Camargo CA Jr, Plewa MC, Nordenholz KE, Moore CL, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med 2010;17:589-97.
26. Kearon C, Ginsberg JS, Douketis J, Turpie AG, Bates SM, Lee AY, et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med 2006;144: 812-21.
27. Yin F, Wilson T, Della Fave A, Larsen M, Yoon J, Nugusie B, et al. Inappropriate use of D-dimer assay and pulmonary CT angiography in the evaluation of suspected acute pulmonary embolism. Am J Med Qual 2012;27:74-9.
28. Dunn KL, Wolf JP, Dorfman DM, Fitzpatrick P, Baker JL and Goldhaber SZ. Normal D-dimer levels in emergency department pa-tients suspected of acute pulmonary embolism. J Am Coll Cardiol 2002;40:1475-8.
29. Hamm CW, Ravkilde J, Gerhardt W, Jørgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of serum troponin T in unstableangina. N Engl J Med 1992;327:146-50.
30. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
31. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008;94:730-6.
32. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptides as an indicator of left ventricular systolic function and long term survival after myocardial infarction: comparison with plasma atrial natriuretic peptide. Circulation 1996;93:1963-9.
33. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treat-ment outcome in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
34. Giannitsis E, Müller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M, et al. Independent prognostic value of cardiac troponin T n patients with confirmed pulmonary embolism. Circulation 2000;102:211-7.
35. Tulevski II, Mulder BJ, van Veldhuisen DJ. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol 2002;39:2080.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.